Reliability and Validity of Thai Calgary Depression Scale of Schizophrenia (CDSS)

The Reliability and Validity of the Thai Version of Calgary Depression Scale for Schizophrenia (CDSS)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01590784

Enrollment

Registered

2012-05-03

Start date

2012-01-31

Completion date

2014-11-30

Last updated

2016-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Keywords

Depression, Schizophrenia

Brief summary

Depression in patients with schizophrenia is common. Several factors was found to be associated with depression including medical illness, quality of life, positive symptoms, and typical antipsychotics. The Calgary depression scale of schizophrenia (CDSS) is commonly used for screening depression in schizophrenia,however; the Thai version of CDSS has not been validated. This study aims to a.) test the reliability and validity of the Thai version of Calgary depression scale of schizophrenia (CDSS) and b.) identify the prevalence and factors associated with depression in patients with schizophrenia including quality of life, type of antipsychotic drugs, and severity of schizophrenia in 60 patients with schizophrenia at the Faculty of Medicine, Chiang Mai University, Thailand.

Detailed description

Measurements: The Thai version of Calgary depression scale of schizophrenia (CDSS), Positive and Negative Syndrome Scale (PANSS), Hamilton Rating Scale for Depression-17 (HAM-D 17), Montgomery-Asberg Depression Rating Scale (MADRS), the Thai abbreviated version of World Health Organization quality of life (WHOQOL-BREF-THAI).

Interventions

None listed

Study design

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* Aged 18 years or over * Diagnosis of schizophrenia according to DSM-IV-TR

Exclusion criteria

* Having organic brain syndrome * Not fluent in Thai

Design outcomes

Primary

Measure	Time frame	Description
The reliability of the Thai version of the Calgary Depression Scale for Schizophrenia (CDSS) in schizophrenia patients.	3 months	The inter-rater reliability, the test-retest reliability will be analyzed.
The validity of the Thai version of the Calgary Depression Scale for Schizophrenia (CDSS) in schizophrenia patients.	3 months	The Positive and Negative Syndrome Scale (PANSS), Hamilton Rating Scale for Depression-17 (HAM-D 17), Montgomery-Åsberg Depression Rating Scale (MADRS) will be administered by the first rater, whereas the CDSS will be assessed by a second independent rater.

Secondary

Measure	Time frame	Description
The prevalence of depression in patients with schizophrenia	3 months	The point prevalence of depression in patients with schizophrenia will be presented in percentage.
The association between depression in schizophrenia and quality of life.	3 months	The association between depression in schizophrenia and quality of life (WHOQOL-BREF-THAI).
The association between depression in schizophrenia and type of antipsychotic drugs.	3 months	The association between depression in schizophrenia and type of antipsychotic drugs (typical vs atypical).
The association between depression in schizophrenia and severity of schizophrenia.	3 months	The association between depression in schizophrenia and severity of schizophrenia (PANSS score).

Countries

Thailand

Outcome results